DWB BODYWIZE LTD
Company number 14720182 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
DWB BODYWIZE LTD - Analysis Report
Company Number: 14720182
Analysis Date: 2025-07-29 18:46 UTC
Credit Opinion: DECLINE
DWB BODYWIZE LTD is a newly incorporated micro-entity with limited trading history and currently reports net liabilities of £3,486 as at 31 March 2024. The company has negative working capital and no employees, indicating minimal operational scale and limited capacity to generate cash flow. The absence of a profit and loss account further restricts insight into earnings or revenue trends. Given the early stage and weak balance sheet, the company poses a high credit risk with no demonstrated ability to service debt or sustain operations independently.Financial Strength:
The balance sheet shows current assets of only £1,662 against current liabilities of £4,998, resulting in net current liabilities of £3,336 and overall net liabilities of £3,486. There are no fixed assets or equity cushions. The negative shareholders’ funds reflect accumulated losses or initial startup costs exceeding capital invested. The company’s financial position is fragile with no substantive asset base to support borrowing.Cash Flow Assessment:
With no employees and minimal current assets, cash inflows are likely limited or nonexistent at this stage. Negative working capital indicates potential liquidity constraints, raising concerns about the company's ability to meet short-term obligations. Without detailed cash flow statements or profit figures, the company’s liquidity position is uncertain but appears weak.Monitoring Points:
- Timely filing of future accounts to track revenue, profitability, and cash flow development.
- Changes in working capital and net assets to assess financial stabilization or deterioration.
- Appointment of additional management or operational staff indicating business scaling.
- Any capital injections or shareholder funding to improve liquidity.
- Payment performance to suppliers or creditors if credit facilities are extended.
Sign in to generate a free AI analysis of this company — no password needed, just an email link.